Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK cells and amniotic epithelial cells in HTLV-1 Associated Myelopathy
NCT02961712Phase 1Unknown
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
- Start
- Jul 2016
- Primary completion
- Oct 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK cell therapy (Anhui Provincial Hospital) in HTLV-1-associated myelopathy (HAM), sponsored by The Second Affiliated Hospital of Fujian Medical University. Primary endpoint: change of Osame's Motor Disability Score at 1 year. Status: unknown.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on NCT02961712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961712.